Modafinil: A Review of Neurochemical Actions and Effects on Cognition
The DOI matches its Crossref record; 215 of the 215 references it cites were found in a registry or an index.
Abstract
Modafinil (2-[(Diphenylmethyl) sulfinyl] acetamide, Provigil) is an FDA-approved medication with wake-promoting properties. Pre-clinical studies of modafinil suggest a complex profile of neurochemical and behavioral effects, distinct from those of amphetamine. In addition, modafinil shows initial promise for a variety of off-label indications in psychiatry, including treatment-resistant depression, attention-deficit/hyperactivity disorder, and schizophrenia. Cognitive dysfunction may be a particularly important emerging treatment target for modafinil, across these and other neuropsychiatric disorders. We aimed to comprehensively review the empirical literature on neurochemical actions of modafinil, and effects on cognition in animal models, healthy adult humans, and clinical populations. We searched PubMed with the search term 'modafinil' and reviewed all English-language articles for neurochemical, neurophysiological, cognitive, or information-processing experimental measures. We additionally summarized the pharmacokinetic profile of modafinil and clinical efficacy in psychiatric patients. Modafinil exhibits robust effects on catecholamines, serotonin, glutamate, gamma amino-butyric acid, orexin, and histamine systems in the brain. Many of these effects may be secondary to catecholamine effects, with some selectivity for cortical over subcortical sites of action. In addition, modafinil (at well-tolerated doses) improves function in several cognitive domains, including workin…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, side effects of alpha agonists like guanfacine and clonidine include high prevalence of somnolence or sedating effects,168,169”
From Report of a Work Group on Sluggish Cognitive Tempo: Key Research Directions and a Consensus Change in Terminology to Cognitive Disengagement Syndrome (2023) · cites this paper as [168]
In the citing paper
“Modafinil, which is approved by the US Food and Drug Administration for the treatment of narcolepsy and its associated daytime sleepiness [59], is a logical candidate to address the hypoactive/sleepy aspects of CDS.”
Citations
Cites
Aston-Jones, G., & Cohen, J. D. (2005) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.28.061604.135709 · Cited by 4,472 · cited 7×
“Importantly, modafinil also augments pupillary dilation parameters (Hou et al, 2005) in a manner consistent with LC phasic responses to task-relevant events (Beatty, 1982a, b; Richer and Beatty, 1987), suggesting the potential for LC/NE system effects in optimizing cognitive task performance, as described in the Aston…”
BackgroundMethodResultInfluentialNarcolepsy in orexin Knockout Mice
Chemelli, R. M., Willie, J. T., Sinton, C. M., Elmquist, J. K., Scammell, T., Lee, C., Richardson, J. A., Williams, S. C., Xiong, Y., Kisanuki, Y., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)81973-x · Cited by 3,095 · cited 3×
“m Fos in orexin neurons in perfornical area 150 mg/kg i.p. Immunohisto-chemistry Mice Chemelli et al, 1999 75 mg/kg i.p. Immunohisto-chemistry Rat Scammell et al, 2000 No binding to orexin-1 receptor IC50 410mM 125I-human-orexin B displacement Transfected Chinese Hamster Ovary cells Wieland et al,…”
BackgroundAston-Jones, G., & Bloom, F. (1981) · The Journal of Neuroscience · doi:10.1523/jneurosci.01-08-00876.1981 · Cited by 1,960 · cited 1×
“It appears also that when levels of tonic LC activity are minimal, such as during sleep, grooming, and eating, that phasic responses are also less robust (Aston-Jones and Bloom, 1981).”
BackgroundTask-evoked pupillary responses, processing load, and the structure of processing resources.
Beatty, J. (1982) · Psychological Bulletin · doi:10.1037/0033-2909.91.2.276 · Cited by 1,959 · cited 1×
“…modafinil also augments pupillary dilation parameters (Hou et al, 2005) in a manner consistent with LC phasic responses to task-relevant events (Beatty, 1982a, b; Richer and Beatty, 1987), suggesting the potential for LC/NE system effects in optimizing cognitive task performance, as described…”
The principal features and mechanisms of dopamine modulation in the prefrontal cortex
Seamans, J. K., & Yang, C. R. (2004) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2004.05.006 · Cited by 1,592 · cited 15×
“Inhibition of DA cell firing in VTA/SN; blocked by Sulpiride 10mM but not by Prazosin 20 mM Extracellular recording Rat brain slice Korotkova et al, 2006 Hyperpolarization of VTA neurons, blocked by Sulpiride 10mM 20–50mM Whole-cell patch clamp Isolated VTA neurons No effect on mesencephalic DA neuron activity 128 mg/…”
BackgroundInfluentialDissociation in prefrontal cortex of affective and attentional shifts
Dias, R., Robbins, T. W., & Roberts, A. C. (1996) · Nature · doi:10.1038/380069a0 · Cited by 1,527
D1 Dopamine Receptors in Prefrontal Cortex: Involvement in Working Memory
Sawaguchi, T., & Goldman-Rakic, P. S. (1991) · Science · doi:10.1126/science.1825731 · Cited by 1,364
The role of histamine and the tuberomamillary nucleus in the nervous system
Haas, H., & Panula, P. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1034 · Cited by 929 · cited 5×
“Thalamic NET occupancy: 16, 44% 5, 8 mg/kg i.v. PET with [11C]MeNER Rhesus monkey Madras et al, 2006 NET binding IC50¼ 35.6mM [3H] NE Human Embryo Kidney No effect on pontine NE neuron activity 128 mg/kg i.p. Single-unit recording Rat (anesthetized) Akaoka et al, 1991 Extracellular NE: m in PFC, medial hypothalamus 12…”
BackgroundInfluentialDopaminergic Role in Stimulant-Induced Wakefulness
Wisor, J. P., Nishino, S., Sora, I., Uhl, G. H., Mignot, E., & Edgar, D. M. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-05-01787.2001 · Cited by 769 · cited 7×
“…extracellular DA levels (measured by microdialysis) that are increased significantly in the rat prefrontal cortex (PFC) (de Saint Hilaire et al, 2001), and in the caudate nucleus of narcoleptic dogs (Wisor et al, 2001), although only minimally in the rat hypothalamus (de Saint Hilaire et al, 2001).”
BackgroundInfluentialThe role of locus coeruleus in the regulation of cognitive performance
Usher, M., Cohen, J. D., Servan-Schreiber, D., Rajkowski, J., & Aston-Jones, G. (1999) · Science · doi:10.1126/science.283.5401.549 · Cited by 715
Research works printed but not linked: 1
- Wong YN, Simcoe D, Hartman LN, Laughton WB, King SP, McCormick GC et al (1999b). A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. J Clin Pharmacol 39: 30–40. · DOI · Paper page
Cited by
Items 201–300 of 735
Modafinil‐induced conditioned place preference via dopaminergic system in mice
Nguyen, T., Tian, Y., You, I., Lee, S., & Jang, C. (2011) · Synapse · doi:10.1002/syn.20892 · Cited by 45
Borghol, A., Aucoin, M., Onor, I., Jamero, D., & Hawawini, F. (2018) · Europe PMC (PubMed Central) · Cited by 45
Schmidt, A., Müller, F., Dolder, P. C., Schmid, Y., Zanchi, D., Liechti, M. E., & Borgwardt, S. (2017) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx037 · Cited by 41
“Many of modafinil’s cognitive and behavioral effects are mediated by adrenergic receptors (Minzenberg and Carter, 2008).”
Drugs currently in Phase II clinical trials for cocaine addiction
Kim, J. H., & Lawrence, A. J. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.915312 · Cited by 44
“D2-like receptors [47-49], and its secondary effects include inhibition of noradrenaline transporters, enhancement of 5-HT function, and stimulation of glutamate and histamine release [46,50,51].”
BackgroundLü, C., Lv, J., Dong, L., Jiang, N., Wang, Y., Fan, B., Wang, F., & Liu, X. (2017) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2017.12.012 · Cited by 42
The warrior in the machine: neuroscience goes to war
Tracey, I., & Flower, R. (2014) · Nature reviews. Neuroscience · doi:10.1038/nrn3835 · Cited by 43
Deficiency of autism-related Scn2a gene in mice disrupts sleep patterns and circadian rhythms
Ma, Z., Eaton, M., Liu, Y., Zhang, J., Chen, X., Tu, X., Shi, Y., Que, Z., Wettschurack, K., Zhang, Z., et al. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105690 · Cited by 35
“While the exact target and mechanism of HU-211 remain to be determined, we suspect that directly or indirectly modulation of glutamate receptor activities by HU-211 may impact sleep homeostasis, considering glutamate concentration and glutamate receptor activity are highly correlated with wakefulness and NREM sleep (F…”
BackgroundEffects of modafinil on simulator driving and self‐assessment of driving following sleep deprivation
Gurtman, C. G., Broadbear, J. H., & Redman, J. R. (2008) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.983 · Cited by 40
“Although the precise mechanisms through which modafinil promotes arousal and modulates cognitive functioning and mood remain unclear, various studies have highlighted the importance of adrenergic dopaminergic, serotonergic, GABAergic and histaminergic activation (Minzenberg and Carter, 2008).”
BackgroundNeuropeptide Systems and Schizophrenia
LaCrosse, A., & Olive, M. F. (2013) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527311312050010 · Cited by 45
“Modafinil is a non-amphetamine- or cocaine-like CNS stimulant that modulates the activity of a host of neurochemical systems, including classical neurotransmitters such as monoamines, glutamate, GABA, and histamine [189], as well as the orexin system [190, 191].”
BackgroundPharmacological Strategies for Enhancing Cognition in Schizophrenia
Barch, D. M. (2010) · Current topics in behavioral neurosciences · doi:10.1007/7854_2010_39 · Cited by 44
“However, modafinil is structurally different than amphetamine, and it is clear that modafinil has effects on many neurotransmitter systems (Minzenberg and Carter 2008), including the ability to inhibit the function of both the dopamine transporter and the norepinephrine transporter, leading to functionally higher leve…”
BackgroundBobo, W. V., Woodward, N. D., Sim, M. Y., Jayathilake, K., & Meltzer, H. Y. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.05.015 · Cited by 41
“norepinephrine efflux in cortical and other brain areas (Minzenberg and Carter, 2008).”
InfluentialTowards Combinatorial Approaches for Preserving Cognitive Fitness in Aging
Brem, A., & Sensi, S. L. (2018) · Trends in Neurosciences · doi:10.1016/j.tins.2018.09.009 · Cited by 39
Neuropharmacology of Sleep and Wakefulness
Watson, C. J., Baghdoyan, H. A., & Lydic, R. (2012) · Sleep Medicine Clinics · doi:10.1016/j.jsmc.2012.06.010 · Cited by 37
Pharmacotherapy for chronic cognitive impairment in traumatic brain injury
Dougall, D., Poole, N. A., & Agrawal, N. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009221.pub2 · Cited by 54
Dopaminergic agents in the treatment of bipolar depression: a systematic review and meta-analysis
Szmulewicz, A. G., Angriman, F., Samamé, C., Ferraris, A., Vigo, D., & Strejilevich, S. A. (2017) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12712 · Cited by 37
“Regarding their mechanism of action, stimulants increase dopaminergic neurotransmission mainly through reuptake inhibition, while stimulant-like agents increase dopamine activity by means of two distinct proposed mechanisms, namely a2 postsynaptic receptor blockade and inhibition of the dopamine transporter (DAT) (34).”
BackgroundPharmacogenomic Biomarkers and Their Applications in Psychiatry
Kam, H., & Jeong, H. (2020) · Genes · doi:10.3390/genes11121445 · Cited by 37
Cognitive enhancing agents in schizophrenia and bipolar disorder
Vreeker, A., van Bergen, A. H., & Kahn, R. S. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.04.014 · Cited by 38
“Modafinil is a novel stimulant that inhibits dopamine and norepinephrine transporters, leading to increased dopamine and norepinephrine efflux in cortical and other brain regions (Minzenberg and Carter, 2008).”
BackgroundNeuroscience of opiates for addiction medicine
Zhou, Y., & Leri, F. (2015) · Progress in brain research · doi:10.1016/bs.pbr.2015.09.001 · Cited by 37
Redrobe, J. P., Bull, S., & Plath, N. (2010) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2010.00146 · Cited by 40
“Pre-clinically, modafinil has displayed pro-cognitive-like activity in a number of behavioral assays thought to address a variety of cognitive domains in “normal” animals (see Minzenberg and Carter, 2008 for review).”
BackgroundMild Cognitive Impairment and Parkinson’s Disease - Something to Remember
Barker, R. A., & Williams‐Gray, C. H. (2015) · Journal of Parkinson s Disease · doi:10.3233/jpd-140427 · Cited by 44
“In the case of the patients with more prominent executive deficits, there has been interest in agents that may have an alerting capacity such as modafanil, [40] as well as drugs targeting the noradrenergic system such as atomoxetine [33].”
Towards a Smart Population: A Public Health Framework for Cognitive Enhancement
Lucke, J. C., & Partridge, B. (2012) · Neuroethics · doi:10.1007/s12152-012-9167-3 · Cited by 41
Pharmacotherapy for Attention-Deficit/Hyperactivity Disorder: From Cells to Circuits
Minzenberg, M. (2012) · Neurotherapeutics · doi:10.1007/s13311-012-0128-7 · Cited by 40
“This literature has been comprehensively reviewed in several available articles [28, 33, 102–105], and due to both space considerations and the present emphasis on neural effects of these medications, the literature is briefly summarized here.”
BackgroundSelf-citationModafinil Prevents Inhibitory Avoidance Memory Deficit Induced by Sleep Deprivation in Rats
Moreira, K. D. M., Ferreira, T. L., Hipólide, D. C., Fornari, R. V., Tufik, S., & Oliveira, M. G. M. (2010) · SLEEP · doi:10.1093/sleep/33.7.990 · Cited by 36
Towards responsible use of cognitive-enhancing drugs by the healthy
Greely, H. T., Sahakian, B. J., Harris, J., Kessler, R. C., Gazzaniga, M. S., Campbell, P., & Farah, M. J. (2012) · Springer eBooks · doi:10.1007/978-94-007-1787-9_14 · Cited by 36
Stolerman, I. P., & Price, L. H. (2015) · Springer eBooks · doi:10.1007/978-3-642-36172-2_200815 · Cited by 36
Tamura, J. K., Carvalho, I. P., Lui, L. M. W., Feng, J. N., Rosenblat, J. D., Mansur, R. B., Lee, Y. L., Cha, D. S., Teopiz, K. M., Ahmad, Z., et al. (2021) · CNS Spectrums · doi:10.1017/s1092852921000092 · Cited by 39
Lee, N., Pennay, A. E., Hester, R., McKetin, R., Nielsen, S., & Ferris, J. (2012) · Drug and Alcohol Review · doi:10.1111/j.1465-3362.2012.00473.x · Cited by 35
“Modafinil may also enhance extracellular monoamine, glutamate and histamine levels, and decrease gamma-aminobutyric acid levels [25].”
BackgroundDepression-like deficits in rats improved by subchronic modafinil
Regenthal, R., Koch, H., Köhler, C., Preiß, R., & Krügel, U. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1493-8 · Cited by 36
“So, awareness is growing that also cognitive dysfunction in treatment-resistant depression or other psychological diseases might be an important treatment target for modafinil (Minzenberg and Carter 2008).”
BackgroundThe Novel Modafinil Analog, JJC8-016, as a Potential Cocaine Abuse Pharmacotherapeutic
Zhang, H., Bi, G., Yang, H.-J., He, Y., Xue, G., Cao, J., Tanda, G., Gardner, E. L., Newman, A. H., & Xi, Z. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.41 · Cited by 37
“All rights reserved 0893-133X/17 www.neuropsychopharmacology.org described as a mild psychostimulant without abuse liability and is also used off label for the treatment of cognitive disorders (Minzenberg and Carter, 2008; Schmaal et al, 2013).”
BackgroundShuman, T., Cai, D. J., Sage, J. R., & Anagnostaras, S. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.07.039 · Cited by 36
A placebo-controlled trial of modafinil for nicotine dependence
Schnoll, R. A., Wileyto, E. P., Pinto, A., Leone, F. T., Gariti, P., Siegel, S. J., Perkins, K. A., Dackis, C. A., Heitjan, D. F., Berrettini, W. H., et al. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.04.008 · Cited by 35
Heal, D. J., & Smith, S. L. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211032475 · Cited by 37
“However, with extremely low potency, that is Ki/IC50 values in the micromolar range (Cao et al., 2016; Karabacak et al., 2015; Minzenberg and Carter, 2008), it is debatable whether this mechanism is clinically irrelevant (Heal et al.”
BackgroundCera, N., Tartaro, A., & Sensi, S. L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107145 · Cited by 35
“Recent studies have indicated that modafinil positively modulates attention, memory, and executive functions [9,10].”
BackgroundPrader-Willi syndrome, excessive daytime sleepiness, and narcoleptic symptoms: a case report
Weselake, S. V., Foulds, J. L., Couch, R., Witmans, M., Rubin, D. A., & Haqq, A. M. (2014) · Journal of Medical Case Reports · doi:10.1186/1752-1947-8-127 · Cited by 33
“The most commonly observed dysfunction is a decreased REM sleep latency and the presence of SOREM periods [9].”
van Enkhuizen, J., Geyer, M. A., Minassian, A., Perry, W., Henry, B. L., & Young, J. W. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.08.008 · Cited by 36
“, 2011b), although a wide array of other receptors may also be involved in the effects of modafinil (Minzenberg and Carter, 2008).”
BackgroundModafinil reinstates a cocaine conditioned place preference following extinction in rats
Bernardi, R. E., Lewis, J. R., Lattal, K. M., & Berger, S. P. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.05.028 · Cited by 32
“Modafinil has also been investigated for use in other neuropsychiatric disorders, such as cocaine addiction [12,17], and thus it has been important to determine whether the neurochemical and behavioral effects of modafinil are similar to those of other psychostimulants, such as cocaine and amphetamine.”
BackgroundCognitive effects of modafinil in patients with multiple sclerosis: A clinical trial.
Ford-Johnson, L., DeLuca, J., Zhang, J., Elovic, E. P., Lengenfelder, J., & Chiaravalloti, N. D. (2016) · Rehabilitation Psychology · doi:10.1037/a0039919 · Cited by 32
Nuijten, M., Blanken, P., van den Brink, W., Goudriaan, A. E., & Hendriks, V. M. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116645268 · Cited by 34
“, 2013), and given its cognitive-enhancing properties (Ballon and Feifel, 2006; Kumar, 2008; Minzenberg and Carter, 2008), treatment with modafinil may be a strategy to improve both cognitive functioning and clinical outcomes in patients with a substance use disorder, including cocaine dependence.”
BackgroundThe off-prescription use of modafinil: An online survey of perceived risks and benefits
Teodorini, R. D., Rycroft, N., & Smith-Spark, J. H. (2020) · PLoS ONE · doi:10.1371/journal.pone.0227818 · Cited by 35
“As modafinil intake results in higher levels of DA, NE, and serotonin [29], it is possible (although highly speculative) that the benefits of these drugs for people with a psychiatric diagnosis may be due to poorer functioning of these neurotransmitter systems.”
BackgroundInfluentialLubec, J., Kalaba, P., Hussein, A. M., Feyissa, D. D., Kotob, M. H., Mahmmoud, R. R., Wieder, O., Garon, A., Sagheddu, C., Ilic, M., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01214-x · Cited by 33
Nunez, N. A., Singh, B., Romo‐Nava, F., Joseph, B., Veldic, M., Cuellar‐Barboza, A., Cabello Arreola, A., Vande Voort, J. L., Croarkin, P., Moore, K. M., et al. (2020) · Bipolar Disorders · doi:10.1111/bdi.12859 · Cited by 31
Use of adjunctive stimulants in adult bipolar depression
Dell'Osso, B., & Ketter, T. A. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000326 · Cited by 31
Nilsson, S. R. O., Heath, C. J., Takillah, S., Didienne, S., Fejgin, K., Nielsen, V., Nielsen, J., Saksida, L. M., Mariani, J., Fauré, P., et al. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0295-3 · Cited by 31
Nakajima, M., Schmitt, L. I., Feng, G., & Halassa, M. M. (2019) · Neuron · doi:10.1016/j.neuron.2019.09.040 · Cited by 34
A Retrospective Review of Supratherapeutic Modafinil Exposures
Carstairs, S. D., Urquhart, A. G., Hoffman, J., Clark, R. F., & Cantrell, F. L. (2010) · Journal of Medical Toxicology · doi:10.1007/s13181-010-0017-6 · Cited by 31
“Unlike amphetamines, modafinil has no effect on spontaneous dopamine release or turnover and lacks peripheral sympathomimetic effects [12, 14, 15].”
BackgroundKalaba, P., Ilić, M., Aher, N. Y., Dragačević, V., Wieder, M., Zehl, M., Wackerlig, J., Beyl, S., Sartori, S. B., Ebner, K., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01938 · Cited by 33
Reichel, C. M., Gilstrap, M. J., Ramsey, L. A., & See, R. E. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2013.09.018 · Cited by 35
“Modafinil also alleviated meth-induced cognitive impairments during withdrawal (Ling et al., 2006; Minzenberg and Carter, 2008; Vocci and Appel, 2007), improved memory (Ghahremani et al., 2011; Kalechstein et al., 2010), and increased attention (Dean et al., 2011) in meth dependent participants.”
BackgroundPharmacological Treatments for Methamphetamine Use Disorder: Current Status and Future Targets
Yates, J. R. (2024) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s431273 · Cited by 32
Michalopoulou, P. G., Lewis, S. W., Wykes, T., Jaeger, J., & Kapur, S. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.03.012 · Cited by 33
Yu, X., Ma, Y., Harding, E. C., Yustos, R., Vyssotski, A. L., Franks, N. P., & Wisden, W. (2019) · SLEEP · doi:10.1093/sleep/zsz031 · Cited by 31
Pharmacological treatment of cognitive deficits in nondementing mental health disorders
Robbins, T. W. (2019) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2019.21.3/trobbins · Cited by 33
Dubljević, V., & Ryan, C. J. (2015) · Neuroscience and Neuroeconomics · doi:10.2147/nan.s61925 · Cited by 33
“It is structurally unrelated to methylphenidate, and evidence suggests that it impacts upon the function of a range of neurotransmitters, including dopamine, noradrenaline, serotonin, glutamate, γ-aminobutyric acid (GABA), and orexin, though the effect of these changes is uncertain.(20) One theory is that modafinil ma…”
BackgroundHerring, W. J., Liu, K., Hutzelmann, J., Snavely, D. B., Snyder, E., Ceesay, P., Lines, C., Michelson, D., & Roth, T. G. (2013) · Sleep Medicine · doi:10.1016/j.sleep.2013.04.010 · Cited by 33
“Modafinil is thought to act primarily through the dopamine transporter, though its precise mechanism of effect is unknown [32].”
BackgroundCognitive enhancers for the treatment of anxiety disorders
Hofmann, S. G., Fang, A., & Gutner, C. A. (2014) · Restorative Neurology and Neuroscience · doi:10.3233/rnn-139002 · Cited by 32
“…effectsontheserotonin,GABA,glutamate,orexin Administrationofmodafinilleadstoanincreasein extracellulardopamine(Volkowetal.,2009), decreasedGABAlevels(Minzenberg&Carter,2008 Modafinilisalsousedoff-labelasapsychostimulantto treatcognitivedysfunctioninvariousmentaldisorders…”
Sauvet, F., Erblang, M., Gomez-Mérino, D., Rabat, A., Guillard, M., Dubourdieu, D., Lefloch, H., Drogou, C., Beers, P. V., Bougard, C., et al. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14098 · Cited by 29
Puyvelde, M. V., Cutsem, J. V., Lacroix, É., & Pattyn, N. (2021) · Military Medicine · doi:10.1093/milmed/usab398 · Cited by 29
Humby, T., & Wilkinson, L. S. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.06.006 · Cited by 32
“Modafinil the awake-promoting drug which has therapeutic potential for ADHD [12] (though not currently approved by the Food and Drug Administration for ADHD) may also act via noradrenergic mechanisms [13].”
BackgroundWake promoting effects of cocaine and amphetamine-regulated transcript (CART)
Keating, G. L., Kuhar, M. J., Bliwise, D. L., & Rye, D. B. (2010) · Neuropeptides · doi:10.1016/j.npep.2009.12.013 · Cited by 31
“5 mg/kg d-amphetamine, 100–128 mg/kg modafinil and 20 mg/ kg GBR-12909 (Edgar and Seidel, 1997; Wisor et al., 2001; Minzenberg and Carter, 2008).”
InfluentialZager, A., Brandão, W. N., Margatho, R. O., Peron, J. P. S., Tufik, S., Andersen, M. L., Kornum, B. R., & Palermo‐Neto, J. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.05.003 · Cited by 31
“The D1 and D2 dopamine receptors have been considered essential for mediating the effect of Modafinil on cognition and stimulation, since these receptors were reported to act cooperatively during wakefulness (Minzenberg and Carter, 2008).”
BackgroundKristofova, M., Aher, Y. D., Ilic, M., Radoman, B., Kalaba, P., Dragačević, V., Aher, N. Y., Leban, J. J., Korz, V., Zanon, L., et al. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.01.032 · Cited by 30
“Over the years modafinil has gained popularity for its reported procognitive effects, which were extensively evaluated in healthy individuals and psychiatric disorders [20,21].”
BackgroundA placebo-controlled study of the modafinil added to risperidone in chronic schizophrenia
Arbabi, M., Bagheri, M., Rezaei, F., Ahmadi-Abhari, S.-A., Tabrizi, M. H., Khalighi‐Sigaroodi, F., & Akhondzadeh, S. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2513-z · Cited by 30
Preliminary evidence for normalization of risk taking by modafinil in chronic cocaine users
Canavan, S. V., Forselius, E., Bessette, A. J., & MORGAN, P. T. (2014) · Addictive Behaviors · doi:10.1016/j.addbeh.2014.02.015 · Cited by 31
“Modafinil is an agent with pro-cognitive effects (Minzenberg & Carter, 2008), and has shown promise in the treatment of cocaine dependence (Mariani & Levin, 2012) in laboratory self-administration studies (Hart, Haney, Vosburg, Rubin & Foltin, 2008) and in doubleblind, placebo-controlled clinical…”
Concordant neurophysiological signatures of cognitive control in humans and rats
Robble, M. A., Schroder, H. S., Kangas, B. D., Nickels, S., Breiger, M., Iturra-Mena, A. M., Perlo, S., Cárdenas, E. F., Der‐Avakian, A., Barnes, S. A., et al. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-00998-4 · Cited by 31
“We then assessed ERPs and spectral changes following both conflict and errors and determined whether modafinil, a drug that enhances some aspects of cognitive function in humans [23], would dose-dependently increase several of these responses including the N200, ERN, and frontal theta power.”
BackgroundMethodInfluentialSharma, A., Muresanu, D. F., Patnaik, R., Menon, P. K., Tian, Z. R., Sahib, S., Nozari, A., Lafuente, J. V., Buzoianu, A. D., Skaper, S. D., et al. (2021) · Progress in brain research · doi:10.1016/bs.pbr.2021.06.003 · Cited by 29
Modafinil ameliorates cognitive deficits induced by maternal separation and sleep deprivation
Garcia, V. A., Hirotsu, C., Matos, G., Alvarenga, T. A., Pires, G. N., Kapczinski, F. P., Schröder, N., Tufik, S. B., & Andersen, M. L. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.07.029 · Cited by 30
Saletu, M., Anderer, P., Saletu-Zyhlarz, G. M., Mandl, M., Saletu, B., & Zeitlhofer, J. (2009) · Sleep Medicine · doi:10.1016/j.sleep.2008.12.005 · Cited by 31
“Varied findings suggest that modafinil may potentiate both DA and NE neurotransmission [21].”
BackgroundInfluentialFörstl, H. (2009) · Der Nervenarzt · doi:10.1007/s00115-009-2801-6 · Cited by 39
Sousa, A. C., & Dinis‐Oliveira, R. J. (2020) · Substance Abuse · doi:10.1080/08897077.2019.1700584 · Cited by 31
Cope, Z. A., Minassian, A., Kreitner, D., MacQueen, D. A., Milienne-Petiot, M., Geyer, M. A., Perry, W., & Young, J. W. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.07.031 · Cited by 27
“The potential pro-cognitive effects of moda fi nil are unlikely to be limited to one domain, (Minzenberg and Carter, 2008; Sahakian and Morein-Zamir, 2015), hence others remain to be tested.”
Abbasowa, L., Kessing, L. V., & Vinberg, M. (2013) · Nordic Journal of Psychiatry · doi:10.3109/08039488.2012.752035 · Cited by 26
McElhiney, M. C., Rabkin, J. G., van Gorp, W. G., & Rabkin, R. (2009) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/13803390903201769 · Cited by 27
“In their comprehensive review of this literature, Minzenberg and Carter (2008) concluded that modafinil “improves function in several This work was partially supported by National Institute of Mental Health (NIMH) Grant R01 MH072383 (J.R.).”
BackgroundOral dosing of rodents using a palatable tablet
Dhawan, S. S., Xia, S., Tait, D. S., Bundgaard, C., Bowman, E., & Brown, V. J. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4863-2 · Cited by 28
“…with schizophrenia and healthy adults (digit span task, CANTAB-Stroop), as well as in experimental animals performing visual attentional tasks and T-maze-serial reversal learning (Minzenberg and Carter 2008; Turner et al. 2003; Randall et al. 2005; Morgan et al. 2007; Beracochea et al. 2002).”
BackgroundMethodReview of the Management of Obstructive Sleep Apnea and Pharmacological Symptom Management
Panahi, L., Udeani, G., Ho, S. S., Knox, B., & Maille, J. M. (2021) · Medicina · doi:10.3390/medicina57111173 · Cited by 29
Modafinil Reduces Neuronal Pyroptosis and Cognitive Decline After Sleep Deprivation
Xiong, X., Zuo, Y., Cheng, L., Yin, Z., Hu, T., Guo, M., Han, Z., Ge, X., Li, W., Wang, Y., et al. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.816752 · Cited by 27
Neuroenhancement of Exposure Therapy in Anxiety Disorders
Hofmann, S. G., Mundy, E. A., & Curtiss, J. E. (2015) · AIMS neuroscience · doi:10.3934/neuroscience.2015.3.123 · Cited by 29
“The improvement in memory performance is dependent on dose and timing, with stronger effects shown with sustained doses of modafinil [77].”
InfluentialModafinil reduces microsleep during partial sleep deprivation in depressed patients
Beck, J., Hemmeter, U., Brand, S., Muheim, F., Hatzinger, M., & Holsboer‐Trachsler, E. (2010) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2010.01.008 · Cited by 29
Tsanov, M., Lyons, D. G., Barlow, S. H., Reyes, R. E. G., & O’Mara, S. M. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.03.010 · Cited by 29
“thoroughly vortexed to ensure homogeneity, asmodafinil is only sparingly soluble in aqueous solution (Minzenberg and Carter, 2007).”
Lohr, J. B., Liu, L., Caligiuri, M. P., Kash, T. P., May, T. A., Murphy, J. D. L. P., & Ancoli‐Israel, S. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.07.039 · Cited by 28
“, 2002), and evidence that noradrenergic systems may be involved as well (Minzenberg and Carter, 2008; Mitchell et al., 2008; Young et al., 2011).”
BackgroundInfluentialSchwartz, T. L., & Goradia, V. (2013) · Drugs in Context · doi:10.7573/dic.212257 · Cited by 27
Humor as a Reward Mechanism: Event-Related Potentials in the Healthy and Diseased Brain
Mensen, A., Poryazova, R., Schwartz, S., & Khatami, R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085978 · Cited by 29
“Modafinil is thought to increase the availability of extra-cellular DA levels by inhibiting DA transporters [57–59], while sodium oxybate primarily acts on the GABAergic system, but may also lead to the increase of DA levels in mesolimbic reward structures through the downstream disinhibition of DA neurons [60].”
BackgroundAcheson, D. T., Twamley, E. W., & Young, J. W. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00103 · Cited by 26
“The primary treatments for schizophrenia are antipsychotic medications, which target psychotic symptoms, but leave patients with considerable disability due to negative and cognitive symptoms (Harvey and Keefe, 2001; Carter, 2005; Keefe et al., 2007; Mintz and Kopelowicz, 2007).”
BackgroundDopamine D1and D2Receptor Family Contributions to Modafinil-Induced Wakefulness
Young, J. W. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.5843-08.2009 · Cited by 26
“Modafinil is currently prescribed in the United States for narcolepsy-associated somnolence, shift-work sleep disorder, and obstructive sleep apnea syndrome (Minzenberg and Carter, 2008), and it is being investigated for treating cognitive dysfunction in schizophrenia, depression, and attention deficit hyperactivity d…”
BackgroundInfluentialNeural and Behavioral Endophenotypes in ADHD
del Campo, N., Müller, U., & Sahakian, B. J. (2012) · Current topics in behavioral neurosciences · doi:10.1007/7854_2012_200 · Cited by 31
Mahmoudi, J., Farhoudi, M., Talebi, M., Sabermarouf, B., & Sadigh‐Eteghad, S. (2014) · Pharmacological Reports · doi:10.1016/j.pharep.2014.11.005 · Cited by 26
“Findings from PET images have vealed that modafinil has an affinity for binding to the brain’s ines transporters [35].”
BackgroundResultChronic modafinil effects on drug-seeking following methamphetamine self-administration in rats
Reichel, C. M., & See, R. E. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000988 · Cited by 28
“…histamine, norepinephrine, adenosine, caminobutyric acid, and serotonin neurotransmitter systems (Gasior et al. 2004; Gatch et al. 2005; Munzar & Goldberg, 1999, 2000 ; Munzar et al. 1999, 2004), and modafinil also interacts with many of these neurotransmitter systems (Minzenberg & Carter, 2008).”
BackgroundBahramnjead, E., Roodsari, S. K., Rahimi, N., Etemadi, P., Aghaei, I., & Dehpour, A. R. (2018) · Neurochemical Research · doi:10.1007/s11064-018-2623-7 · Cited by 26
Zager, A. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2020.04.038 · Cited by 26
“These negative effects on GABAergic transmission were likely correlated to increased brain levels of glutamate and serotonin promoted by modafinil (Kumar, 2008; Minzenberg and Carter, 2008).”
BackgroundWang, D., Bai, X. X., Williams, S. C., Hua, S. C., Kim, J.-W., Marshall, N. S., D'Rozario, A. L., & Grunstein, R. R. (2015) · SLEEP · doi:10.5665/sleep.4912 · Cited by 26
Dell’Osso, B. M., Timtim, S., Hooshmand, F., Miller, S., Wang, P. W., Hill, S. J., Portillo, N., & Ketter, T. A. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.11.030 · Cited by 26
“Modafinil (2-(benzhydrylsulfinyl) acetamide) is a stimulantlike agent, previously thought to primarily enhance dopaminergic and noradrenergic neurotransmission, secondarily enhance serotonergic, glutamatergic and histaminergic neurotransmission, and influence orexinergic neurotransmission (Minzenberg and Carter, 2008).”
BackgroundPsychostimulant Use Disorder, an Unmet Therapeutic Goal: Can Modafinil Narrow the Gap?
Hersey, M., Bacon, A. K., Bailey, L. G., Coggiano, M. A., Newman, A. H., Leggio, L., & Tanda, G. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.656475 · Cited by 25
Strategies for Treatment of Disease-Associated Dementia Beyond Alzheimer's Disease: An Update
Khan, S. S., Khatik, G. L., & Datusalia, A. K. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220411083922 · Cited by 31
“Affects the catecholamines, serotonin, glutamate, gamma amino-butyric acid, orexin, and histamine systems [74].”
Sulfoxides and disulfides from sulfenic acids: Synthesis and applications
Gangemi, C. M. A., D’Agostino, E., Aversa, M. C., Barattucci, A., & Bonaccorsi, P. M. (2023) · Tetrahedron · doi:10.1016/j.tet.2023.133550 · Cited by 25
Micoulaud, F. G. (2015) · Journal of Clinical Research & Bioethics · doi:10.4172/2155-9627.1000213 · Cited by 29
“Effects on glutamate, histamine and orexin/hypocretin have also been evocated [28,29].”
BackgroundEfficacy of off-label augmentation in unipolar depression: A systematic review of the evidence
Kleeblatt, J., Betzler, F., Kilarski, L. L., Bschor, T., & Köhler, S. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.03.003 · Cited by 28
“However, this effect is less pronounced compared to other psychostimulants, so the risk of abuse or side effects is smaller (Minzenberg and Carter, 2008).”
Memory creation and modification: Enhancing the treatment of psychological disorders.
Kredlow, M. A., Eichenbaum, H., & Otto, M. W. (2018) · American Psychologist · doi:10.1037/amp0000185 · Cited by 25
“It is a psychostimulant that amplifies the release of glutamate and serotonin and inhibits the release of gamma-aminobutyric acid (Minzenberg & Carter, 2008).”
Healthy Brain Aging: What Has Sleep Got To Do With It?
Malhotra, R. K., & Desai, A. K. (2010) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2009.11.001 · Cited by 26
Acute Effects of Methylphenidate, Modafinil, and MDMA on Negative Emotion Processing
Schmidt, A., Müller, F., Dolder, P. C., Schmid, Y., Zanchi, D., Egloff, L., Liechti, M. E., & Borgwardt, S. (2017) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx112 · Cited by 26
“, 2017), even though 200 mg is typically used for cognitive enhancing purposes in healthy subjects (Minzenberg and Carter, 2008) and related to task enjoyment (Müller et al.”
BackgroundInfluentialKouhnavardi, S., Ecevitoglu, A., Dragačević, V., Sanna, F., Arias‐Sandoval, E., Kalaba, P., Kirchhofer, M., Lubec, J., Niello, M., Holy, M., et al. (2022) · Biomolecules · doi:10.3390/biom12070881 · Cited by 25
“Thus, while a great deal of attention has been paid to modafinil in both experimental and clinical/applied research [151,152], several limitations regarding the effectivity and degree of specificity of modafinil have encouraged the search for alternative modafinil analogues and other molecules acting on the DAT signal…”
BackgroundAn update on potential pharmacotherapies for cognitive impairment in bipolar disorder
Johnson, D. E., McIntyre, R. S., Mansur, R. B., & Rosenblat, J. D. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2194488 · Cited by 25
“nia, with improvements in attentional set-shifting, working memory, response inhibition, executive function, immediate recall, verbal fluency, and short-term visual memory [94].”
BackgroundKardani, F., Khezeli, T., Shariati, S., Hashemi, M. B., Mahdavinia, M., jelyani, A. Z., Rashedinia, M., Noori, S. M. A., Karimvand, M. N., & Ramezankhani, R. (2024) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2024.116005 · Cited by 25
Metadata
- Authors
- Minzenberg, M. J., & Carter, C. S.
- Affiliations
- University of California Davis Medical Center (US)
- Corresponding author
- Minzenberg, Michael J
- Venue
- Neuropsychopharmacology
- Published
- 2007-08-22
- Volume
- 33
- Issue
- 7
- Pages
- 1477-1502
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2122011624
- Semantic Scholar
- cf5b2a15296e7832bcfdd965f28583772ef2999c
- Cited by
- 713
- References
- 215
- Citations by year
- 2026: 18 · 2025: 32 · 2024: 25 · 2023: 33 · 2022: 33 · 2021: 46 · 2020: 26 · 2019: 19 · 2018: 33 · 2017: 42 · 2016: 22 · 2015: 49 · 2014: 48 · 2013: 62 · 2012: 59
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (MH 59883, MH066629, R01MH059883, R01MH066629)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Social Sciences › Arts and Humanities › Philosophy › Neuroethics, Human Enhancement, Biomedical Innovations
- Life Sciences › Neuroscience › Cognitive Neuroscience › Sleep and Wakefulness Research
- Keywords
- modafinil, wakefulness-promoting agents, neurochemical mechanisms, cognition, catecholamines, serotonin, glutamate, GABA, orexin, histamine, working memory, episodic memory, prefrontal cortex, cognitive control, treatment-resistant depression, attention deficit hyperactivity disorder, schizophrenia, cognitive impairment, pharmacokinetics, abuse liability
- MeSH terms
- Modafinil, Animals, Mental Disorders, Benzhydryl Compounds, Brain Chemistry, Cognition, Humans, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.